Erin Schenk, MD, PhD
222 posts
Erin Schenk, MD, PhD
@SchenkLab
Thoracic Med Onc | Scientist @CUAnschutz | My lab studies the interface between the immune system and lung cancer | Immunotherapy enthusiast | @MayoHemeOnc Alum
CU Anschutz Medical Center Sumali Ağustos 2019
536 Sinusundan624 Mga Tagasunod
Thrilled to be part of the Lung TeamLab and the incredible collaboration to eliminate residual disease!
𝗕𝗿𝗲𝗮𝗸 𝙏𝙝𝙧𝙤𝙪𝙜𝙝 𝗖𝗮𝗻𝗰𝗲𝗿@break_cancer
Today we launch the PoweRD 2 Cure ALK+ Lung Cancer TeamLab! Uniting researchers from @DanaFarber @MDAndersonNews @kochinstitute @KimmelCancerCtr @MSKCancerCenter @BostonChildrens @MGHCancerCenter @CUCancerCenter @VUMC_Cancer in radical collaboration to target residual lung cancer cells remaining after initial therapy. Read more: breakthroughcancer.org/2024/12/break-…
English
The promise of immune-based therapies still needs to reach patients with NSCLC bearing driver alterations. We need to look beyond checkpoint inhibitors. Thank you @NarjustFlorezMD and @BiagioRicciutMD
for the amazing discussion! #LCSM
Narjust Florez, MD, FASCO@NarjustFlorezMD
I hope you are ready for this discussion with Drs. @SchenkLab & @BiagioRicciutMD I learned SO much only in the first 5 minutes of this conversation about the use of IO in patients with NSCLC and driver mutations. Including -Toxicity -Importance of NGS -Prognostic and predictive markers -The impact of tumor microenvironment Lung Cancer Considered the official @IASLC podcast ⌛️💉🧬🧫🧪
English
Don’t miss out! My colleague @TejasPatilMD presenting his exciting work on early MET bypass signaling in ALK and RET driven NSCLC. He is also an @CUCancerCenter Rising Star! @LUNGevity @ALKPositiveinc @RETpositive #LCSM #AACR24
English
@thehuffproject @LUNGevity @Joshua_Reuss my colleague in arms against lung cancer is doing amazing work to unravel who can benefit from IO/VEGF therapy in his IIT and is supported by @thehuffproject and @LUNGevity. Josh let's talk translation and upping my wall art game 😁
English
Thank you to @thehuffproject and @LUNGevity for supporting my career development award. Fantastic experience today sharing with @thehuffproject about the work my lab has been able to do #LCSM #ALKpositve
English
@NarjustFlorezMD @MayoHemeOnc Thanks for putting up a picture where we both look good... that is a TRUE friend
English
Erin Schenk, MD, PhD nag-retweet
@MayoHemeOnc gave me a thoracic oncology sister for life!
Dr. @SchenkLab
Fancy breakfast and soulful conversations.
#TTLC24
Santa Monica, CA 🇺🇸 English
@TejasPatilMD @WadeIams @MMarmarelis @DRCamidge @LUNGevity @EGFRSummit @EGFRResisters @ALKPositiveinc @ALKpositiveINT @ros1cancer @RETpositive @lcsmchat @OncoAlert Congratulations Tejas! Look forward to future collaborations
English
HUGE thanks to @SchenkLab, @WadeIams, @MMarmarelis, @DRCamidge for their input into this work! Major thanks to @LUNGevity for grant support! @EGFRSummit @EGFRResisters @ALKPositiveinc @ALKpositiveINT @ros1cancer @RETpositive @lcsmchat @OncoAlert
English
I'm thrilled to share our article "The Efficacy and Safety of Treating Acquired MET Resistance Through Combinations of Parent and MET Tyrosine Kinase Inhibitors in Patients With Metastatic Oncogene-Driven NSCLC" - now in @JTOonline!
➡️#supplementaryMaterial" target="_blank" rel="nofollow noopener">jtocrr.org/article/S2666-…
👇🏾DETAILS BELOW!
English
One of the best parts of this job is seeing your mentees succeed. Keep up the great work Patrick and Amaie (not pictured but proud to say he got into pharmacy school!). Hearing from both made my day
English
English
Thanks to @VivekSubbiah for giving @JackWestMD and I a chance to channel our debates into surprising consensus! #LCSM
Lessons from ADAURA: Can we improve on a positive trial? - West and Pennell - Cancer acsjournals.onlinelibrary.wiley.com/doi/10.1002/cn…
English
Just submitted a large external grant. Because I care about my #worklifebalance, I'm going to give myself 15 hours off before starting on the next grant🙃🤣 #science #PILife #ButIStillLoveIt
English
Thank you @ALKPositiveinc! Currently in the lab working towards new plans
ALK Positive@ALKPositiveinc
ALK+ #lungcancer patients like having plans A, B and C all lined up. #Research helps us do this. Ultimately, as Dr Erin Schenk of @SchenkLab says, research helps us do better for our patients not only today… but tomorrow. It's really about #MoreResearchMoreLife #LCAM
English
@RielyMD @TommyJohn00 @FordePatrick I didn’t like how this data was buried in the ADAURA supplemental figures. Forgoing chemotherapy in patients with an opportunity to benefit feels like leaving money on the table.
English
@TommyJohn00 @FordePatrick If you look at supplementary data for ADAURA, and you dig out patients with stage II/III (i.e. the ones for whom chemotherapy has proven efficacy), you see that chemo definitely seems to add. Here's a table I made of the relevant 5 year OS
English
ALINA adjuvant alectinib vs chemo for ALK pos resected lung cancer. Again unfortunate re data leak but sneak peak looks good. HR 0.24 favoring alectinib 30% improvement in DFS at 3 yrs. Adjuvant chemo followed by alectinib likely the path forward.
English
@TejasPatilMD @EGFRResisters @DRCamidge Great highlights @TejasPatilMD. We also need to start thinking beyond our current CPI for EGFR+ NSCLC. Novel IO agents with different mechanisms of action are being developed and we need to encourage sponsors to open trial arms for EGFR/ALL/ROS1 etc
English
My takeaways: (1) If molecular unknown, leave out IO and give chemo while waiting. (2) Does tox vary by IO used? (3) Can we better define pneumonitis risk (see EOPE trial). (4) IO in resectable #EGFR NSCLC? #lcsm
@EGFRResisters @SchenkLab @DRCamidge
👉🏾pubmed.ncbi.nlm.nih.gov/33307191/
English
Lots of new data on #EGFR NSCLC @myESMO; I want to highlight an important 2019 study @SocietyofMSKCC. Highlights risk of toxicity with IO given before #osimertinib. I think it nicely frames issues related to ICI exposure among resectable #EGFR #LungCancer . [THREAD]
English
English
Come join us @Hilton Denver City on Oct 14th 2023 for #MLSDenver Conference! I'll excited to discuss later line therapies for NSCLC (i.e. what to do when 1st line treatment fails) and #ADCs! @mecmededucation #OncTwitter #LCSM
English
@DrChoueiri I also find, “If you’re going through hell, keep going,” another great Churchill quote about how to persevere and stay on track.
English
“You’ll never reach your destination if you throw stones at every dog who barks.” —Sir Winston Churchill (1874-1965)
English
I often share the words of a mentor/hero of mine (a hematologist) in my clinical practice as a thoracic oncologist:
“It is better to start the right treatment rather than the fast one.”
Stephen V Liu, MD@StephenVLiu
More data showing the importance of *waiting* for NGS results before starting NSCLC therapy whenever possible! Retrospective analysis @JCOOP_ASCO show that when treatment of driver+ NSCLC before biomarker results is associated with inferior survival. ascopubs.org/doi/abs/10.120…
English
@dwightowenmd @OBRtweets @ASCO @ns_chd Great interview, Dwight! Building these guidelines, helping them be accessible and clear is an incredible challenge as our field evolves. Glad to be in the trenches with you on this. We can do it! @ASCO
English
Was great meeting with Dr. Figlin on the @OBRtweets Peer-spectives podcast to discuss the fast moving field of #NSCLC and how the @ASCO Living Guidelines can be an added resource to guide clinical decision making! @ns_chd
obroncology.com/podcast/really…
English